An integrated microfluidic electrochemiluminescence device for point-of-care testing of acute myocardial infarction

Lihang Zhu; Wenxuan Fu; Boyu Zhu; Qian Feng; Xudong Ying; Shuang Li; Jing Chen; Xiaoya Xie; Chenying Pan; Jun Liu; Chao Chen; Xing Chen; Danhua Zhu

doi:10.1016/j.talanta.2023.124626

An integrated microfluidic electrochemiluminescence device for point-of-care testing of acute myocardial infarction

Talanta. 2023 Sep 1:262:124626. doi: 10.1016/j.talanta.2023.124626. Epub 2023 May 6.

Authors

Lihang Zhu¹, Wenxuan Fu², Boyu Zhu², Qian Feng³, Xudong Ying², Shuang Li⁴, Jing Chen⁵, Xiaoya Xie⁶, Chenying Pan⁶, Jun Liu⁶, Chao Chen⁷, Xing Chen⁸, Danhua Zhu⁹

Affiliations

¹ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine; Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, 310003, Zhejiang, China; Department of Biomedical Engineering, Key Laboratory of Biomedical Engineering of Ministry of Education of China, Zhejiang Provincial Key Laboratory of Cardio-Cerebral Vascular Detection Technology and Medicinal Effectiveness Appraisal, Zhejiang University, Hangzhou, 310027, Zhejiang, China.
² Institute of Analytical Chemistry, Department of Chemistry, Key Laboratory of Excited-State Materials of Zhejiang Province, Zhejiang University, Hangzhou, 310058, Zhejiang, China.
³ Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang, China.
⁴ Academy of Medical Engineering and Translational Medicine, Tianjin University, 300072, Tianjin, China.
⁵ School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
⁶ Department of Biomedical Engineering, Key Laboratory of Biomedical Engineering of Ministry of Education of China, Zhejiang Provincial Key Laboratory of Cardio-Cerebral Vascular Detection Technology and Medicinal Effectiveness Appraisal, Zhejiang University, Hangzhou, 310027, Zhejiang, China.
⁷ GuoZhen Health Technology Co., Ltd, 100142, Beijing, China.
⁸ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine; Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, 310003, Zhejiang, China; Department of Biomedical Engineering, Key Laboratory of Biomedical Engineering of Ministry of Education of China, Zhejiang Provincial Key Laboratory of Cardio-Cerebral Vascular Detection Technology and Medicinal Effectiveness Appraisal, Zhejiang University, Hangzhou, 310027, Zhejiang, China. Electronic address: cnxingchen@zju.edu.cn.
⁹ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine; Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, 310003, Zhejiang, China. Electronic address: zhudanhua@zju.edu.cn.

PMID: 37244239
DOI: 10.1016/j.talanta.2023.124626

Abstract

Heart-type fatty acid binding protein (H-FABP) is an early biomarker for acute myocardial infarction. The concentration of H-FABP in circulation sharply increases during myocardial injury. Therefore, fast and accurate detection of H-FABP is of vital significance. In this study, we developed an electrochemiluminescence device integrated with microfluidic chip (designed as m-ECL device) for on-site detection of H-FABP. The m-ECL device is consisted of a microfluidic chip that enable easy liquid handling as well as an integrated electronic system for voltage supply and photon detection. A sandwich-type ECL immunoassay strategy was employed for H-FABP detection by using Ru (bpy)₃²⁺ loaded mesoporous silica nanoparticles as ECL probes. This device can directly detect H-FABP in human serum without any pre-treatment, with a wide linear range of 1-100 ng/mL and a low limit of detection of 0.72 ng/mL. The clinical usability of this device was evaluated using clinical serum samples from patients. The results obtained from m-ECL device are well matched with those obtained from ELISA assays. We believe this m-ECL device has extensive application prospects for point-of-care testing of acute myocardial infarction.

Keywords: Electrochemiluminescence; Heart-type fatty acid binding protein; Lab on a chip; Microfluidic device; Point-of-care testing.

MeSH terms

Biosensing Techniques* / methods
Fatty Acid Binding Protein 3
Humans
Immunoassay / methods
Luminescent Measurements / methods
Microfluidics
Myocardial Infarction* / diagnosis
Point-of-Care Testing

Substances

Fatty Acid Binding Protein 3